戻る
Aspira Women's Health Inc (AWHL) 収入
AWHL 株価推移チャート
AWHL 収入
Aspira Women's Health Inc
$0.34
-2.84%
$-0.01
終値： Apr 01, 16:00:00 GMT-4
$0.34
0%
$0
アフターマーケット：Apr 01, 20:00:00 GMT-4
最新の利益結果: Q3 '24
報告済み: 2024-11-19
歴史的収益
四半期
年次
EPS
収入
Earnings FAQ
AWHLの最近の1株当たり利益（EPS）は予想と比較してどうでしたか？
Aspira Women's Health Inc AWHLの前四半期の収益はどうでしたか？
Aspira Women's Health Incの収益見積もりはいくらですか？
Aspira Women's Health Incの収益品質スコアはどれくらいですか？
Aspira Women's Health Incはいつ収益を報告しますか？
Aspira Women's Health Incの予想収益はいくらですか？
Aspira Women's Health Incは収益予想を上回りましたか？
主要データ
前終値
$0.3551
始値
$0.3525
当日レンジ
$0.345 - $0.3525
52週レンジ
$0.02 - $0.71
取引高
16
平均取引高
51.4K
配当利回り
--
1株当たり利益(TTM)
-0.99
時価総額
$20.4M
AWHLとは何ですか？
Aspira Women's Health, Inc. engages in the provision of bio-analytic and diagnostic services. The company is headquartered in Austin, Texas and currently employs 66 full-time employees. The company went IPO on 2000-09-29. The firm's portfolio includes OvaWatch and the Ova1Plus workflow, offered to clinicians as OvaSuite. OvaWatch is used to assess ovarian cancer risk for women with an adnexal mass where their initial clinical assessment indicates the mass is indeterminate or benign. The Ova1Plus is a reflex process of two tests, Ova1 and Overa, to assess the risk of ovarian malignancy in women with an adnexal mass planned for surgery. Its product pipelines are OVAinform and ENDOinform. OVAinform is a test that combines serum proteins, clinical data (metadata), and miRNA for assessing the risk of ovarian cancer in women with an adnexal mass. ENDOinform is a test program that combines serum proteins, clinical data (metadata), and miRNA for the identification of endometriosis.